Andréa Varga

6.5k citations

107 papers · 4.6k indexed · 4 hit papers · h-index 33

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 74
- Cancer Immunotherapy and Biomarkers 28
- Colorectal Cancer Treatments and Studies 16
- HER2/EGFR in Cancer Research 15
- Cancer Treatment and Pharmacology 10
Cancer Research 28
- Cancer Genomics and Diagnostics 18

Co-authors: Sarina A. Piha‐Paul Jean‐Charles Soria Patrick A. Ott Sanatan Saraf Hope S. Rugo Christophe Le Tourneau Jean‐Marie Michot Antoine Hollebecque
Journals: Journal of Clinical Oncology (28 papers)Annals of Oncology (18 papers)Cancer Research (10 papers)European Journal of Cancer (7 papers)Investigational New Drugs (5 papers)
Partner nations: France United States Spain

In The Last Decade

Andréa Varga

103 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies 2020 · 335 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 International Journal of Cancer
2019 JAMA Oncology
2018 The Lancet Oncology
2017 Journal of Clinical Oncology

Peers

Countries citing papers authored by Andréa Varga

Since Specialization

Citations

This map shows the geographic impact of Andréa Varga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andréa Varga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andréa Varga more than expected).

Fields of papers citing papers by Andréa Varga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andréa Varga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andréa Varga. The network helps show where Andréa Varga may publish in the future.

Co-authors

The 25 scholars most cited alongside Andréa Varga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andréa Varga Line = papers co-authored together Andréa Varga links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients Cancer Immunology Immunotherapy ·Pierre Rosenbaum, Cécile Artaud, Sylvie Bay, Christelle Ganneau, Mario Campone, Suzette Delaloge, Carole Gourmelon, Delphine Loirat, Jacques Médioni, F Pein, Marie‐Paule Sablin, Olivier Trédan, Andréa Varga, Claude Leclerc	2020	41
2	66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL Annals of Oncology ·Cyril Quivoron, Jean‐Marie Michot, Valérie Camara‐Clayette, Alina Danu, Julien Lazarovici, Clémentine Sarkozy, David Ghez, Julien Rossignol, Capucine Baldini, P. Martin Romano, Andréa Varga, Sophie Cotteret, Peggy Dartigues, Christophe Massard, Vincent Ribrag	2020	1
3	1050P Does immunotherapy impact the outcomes of future anti-tumour therapies? Annals of Oncology ·Manuela Tiako Meyo, Roger Sun, Stéphane Champiat, Jean‐Marie Michot, Capucine Baldini, Anas Gazzah, Rastislav Bahleda, Patricia Martín-Romano, Antoine Hollebecque, Andréa Varga, Aurélien Marabelle, Christophe Massard	2020	1
4	A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Andréa Varga, Jean‐Charles Soria, Antoine Hollebecque, Patricia LoRusso, Johanna C. Bendell, Shih-Min A. Huang, Marie-Claire Wagle, Kwame Okrah, Lichuan Liu, Elaine Murray, Sandra Sanabria Bohórquez, Michael Tagen, Hatem Dokainish, Lars Müeller, Howard A. Burris	2019	64
5	MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma Journal of Thoracic Oncology ·Andréa Varga, Gérard Zalcman, Carlos Gomez‐Roca, Samy Ammari, Caroline Caramella, V. Gounant, Audrey Rabeau, Xavier Paolettí, Capucine Baldini, Patricia Martín-Romano, Stéphane Champiat, Perrine Vuagnat, Jean‐Marie Michot, Laura Mezquita, Christophe Massard, Benjamin Besse, J.C. Soria, Aurélien Marabelle, David Planchard	2019	1
6	Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer BMC Cancer ·Janice M. Mehnert, Andréa Varga, Marcia S. Brose, Rahul Aggarwal, Chia‐Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha‐Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam	2019	148
7	Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation Clinical Cancer Research ·Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andréa Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah, Jean‐Marie Michot, Sophie Postel‐Vinay, Eric Angevin, Vincent Ribrag, Antoine Hollebecque, Jean‐Charles Soria, Caroline Robert, Christophe Massard, Aurélien Marabelle	2018	106
8	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours European Journal of Cancer ·H. Herin, Sandrine Aspeslagh, Eduardo Castañón, Valérie Dyevre, Aurélien Marabelle, Andréa Varga, S. P. Vinay, Jean‐Marie Michot, Vincent Ribrag, Anas Gazzah, Rastilav Bahleda, Olivier Mir, Christophe Massard, Antoine Hollebecque, Jean‐Charles Soria, Capucine Baldini	2018	20
9	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial Journal of Clinical Oncology ·Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil, Patrick A. Ott, Sarina A. Piha‐Paul, Carlos Gomez‐Roca, Emilie M.J. van Brummelen, Hope S. Rugo, Shari Thomas, Sanatan Saraf, Reshma Rangwala, Andréa Varga Hit paper breakdown →	2017	386
10	P3.02b-115 Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib Journal of Thoracic Oncology ·Shirish M. Gadgeel, Wei Chen, Zofia Piotrowska, Jonathan W. Goldman, Heather A. Wakelee, D. Ross Camidge, Andréa Varga, Helena A. Yu, Vassiliki A. Papadimitrakopoulou, Joel W. Neal, Jean‐Charles Soria, Antoinette J. Wozniak, Gregory J. Riely, Vignesh Narayanan, Melody Mendenhall, Lecia V. Sequist	2017	3
11	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study European Journal of Cancer ·Eric Angevin, Philippe A. Cassier, Antoîne Italiano, Anthony Gonçalvès, Anas Gazzah, C. Terret, Maud Toulmonde, Gwénaëlle Gravis, Andréa Varga, Cédric Parlavecchio, Angélo Paci, Vianney Poinsignon, Jean‐Charles Soria, Damien Drubay, Antoine Hollebecque	2017	12
12	Prognostic factors and outcome of patients with hematological malignancies in phase I trials Anti-Cancer Drugs ·Lina Benajiba, Jean‐Marie Michot, Capucine Baldini, Laura Faivre, Andréa Varga, Rastilav Balheda, Anas Gazzah, Ecaterina Ileana, Sophie Postel‐Vinay, Christophe Massard, Stéphane de Botton, Jean‐Charles Soria, Vincent Ribrag	2017	0
13	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) European Journal of Cancer ·Frédéric Bigot, Eduardo Castañón, Capucine Baldini, Antoine Hollebecque, Alberto Carmona‐Bayonas, Sophie Postel‐Vinay, Eric Angevin, Jean‐Pierre Armand, Vincent Ribrag, Sandrine Aspeslagh, Andréa Varga, Rastislav Bahleda, Jessica Menis, Anas Gazzah, Jean‐Marie Michot, Aurélien Marabelle, Jean‐Charles Soria, Christophe Massard	2017	145
14	Rociletinib-associated cataracts in EGFR-mutant NSCLC Annals of Oncology ·Zofia Piotrowska, E. Liu, Andréa Varga, Manish Thakur, V. Narayanan, Stephen V. Liu, Joel W. Neal, Marshall L. Spiegel, Benjamin Solomon, Helena A. Yu, S.-H.I. Ou, Vassiliki A. Papadimitrakopoulou, Shirish M. Gadgeel, D. Ross Camidge, J.C. Soria, Heather A. Wakelee, Jonathan W. Goldman, Kamden R. Kopani, Lindsey Rolfe, Lecia V. Sequist	2016	2
15	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma Nature Communications ·Joonil Jung, Joon Sang Lee, Mark A. Dickson, Gary K. Schwartz, Axel Le Cesne, Andréa Varga, Rastilav Bahleda, Andrew J. Wagner, Edwin Choy, Maja J. De Jonge, Madelyn Light, Steve Rowley, Sandrine Macé, James Watters	2016	78
16	Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials International Journal of Cardiology ·Antoine Hollebecque, Émilie Lanoy, Frederic Troallen, Laurie Soulat-Dufour, Christophe Massard, Rastislav Bahleda, Andréa Varga, Anas Gazzah, Sophie Postel‐Vinay, Vincent Ribrag, Éric Deutsch, Eric Angevin, Franck Boccara, Ariel Cohen, Jean‐Charles Soria, Stéphane Éderhy	2016	0
17	Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM) Annals of Oncology ·David Planchard, Fabrice Barlési, Carlos Gomez‐Roca, Julien Mazières, Andréa Varga, Laurent Greillier, Nathalie Chaput, Cédric Parlavecchio, K. Malekzadeh, Maud Ngo‐Camus, Sarah Zahi, Benjamin Besse, Émilie Lanoy, J.C. Soria	2016	13
18	Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours British Journal of Cancer ·Rastislav Bahleda, Antoine Hollebecque, Andréa Varga, Anas Gazzah, Christophe Massard, Éric Deutsch, Nadia Amellal, Françoise Farace, Mahmoud Ould-Kaci, Flavien Roux, Kristell Marzin, Jean‐Charles Soria	2015	16
19	A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Vincent Ribrag, Jehan Dupuis, Hervé Tilly, Franck Morschhauser, Fabrice Lainé, Roch Houot, Corinne Haïoun, Christiane Copie, Andréa Varga, John M. Lambert, Laurence Hatteville, Samira Ziti‐Ljajic, Anne Caron, Sandrine Payrard, Bertrand Coiffier	2013	79
20	Low skeletal muscle is associated with toxicity in patients included in phase I trials Investigational New Drugs ·Sophie Cousin, Antoine Hollebecque, Serge Koscielny, Olivier Mir, Andréa Varga, Vickie E. Baracos, Jean‐Charles Soria, S. Antoun	2013	61

About Andréa Varga

Andréa Varga is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Biological Psychiatry, having authored 107 papers that have together received 4.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (28 papers), Lung Cancer Treatments and Mutations (23 papers), Cancer Genomics and Diagnostics (18 papers), Colorectal Cancer Treatments and Studies (16 papers), HER2/EGFR in Cancer Research (15 papers), Advanced Breast Cancer Therapies (13 papers), Cancer Treatment and Pharmacology (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). The work is most often cited by research in Oncology (3.0k citations), Immunology (816 citations), Pulmonary and Respiratory Medicine (1.2k citations), Cancer Research (547 citations) and Reproductive Medicine (257 citations). Andréa Varga has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Sarina A. Piha‐Paul, Jean‐Charles Soria, Patrick A. Ott, Sanatan Saraf, Hope S. Rugo, Christophe Le Tourneau, Jean‐Marie Michot, Antoine Hollebecque, Emilie M.J. van Brummelen and Christophe Massard. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact